Repeat Dosing of Psilocybin in Migraine Headache

This randomised, parallel-design study evaluates up to two oral doses of psilocybin (10 mg) compared with diphenhydramine placebo in adults with migraine to assess clinical efficacy and biological mechanisms.

Neuroinflammatory markers relevant to migraine will be measured to explore potential anti-inflammatory mechanisms that may underlie clinical effects; outcomes will inform larger future trials.